Literature DB >> 29998802

Elevated C-reactive Protein and Depressed High-density Lipoprotein Cholesterol are Associated with Poor Function Outcome After Ischemic Stroke.

Xiaowei Zheng1, Nimei Zeng1, Aili Wang1, Zhengbao Zhu1, Chongke Zhong1,2, Tan Xu1, Tian Xu1,3, Yanbo Peng4, Hao Peng1, Qunwei Li5, Zhong Ju6, Deqin Geng7, Yonghong Zhang1, Jiang He2.   

Abstract

AIMS: C-reactive protein is an established marker of inflammation that can impair the protective function of High Density Lipoprotein Cholesterol (HDL-C). The combined effect of Creactive protein and HDL-C on long-term outcomes in patients with stroke remains uncertain.
METHODS: A total of 3124 acute ischemic stroke subjects from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) were included in this analysis. Participants were divided into four groups according to CRP and HDL-C levels on admission. The primary outcome was a combination of death and major disability (modified Rankin Scale score ≥3) at one year after stroke.
RESULTS: Compared to participants with low CRP/ high HDL-C, adjusted odd ratios for primary outcome for those with low CRP /low HDL-C, high CRP /high HDL-C and high CRP /low HDL-C were 1.06(0.81-1.39),1.78(1.31-2.41) and 2.03(1.46-2.80), respectively, after multiple adjustments. Adding serum CRP and HDL-C status to a model containing conventional stroke risk factors significantly improve risk reclassification for the combined outcome of death and major disability (NRI: 6.85%, P=0.005; IDI: 2.57%, P=0.002). Moreover, no interaction was observed between CRP and HDL-C in relation to stroke outcomes (P-interaction >0.05 for all).
CONCLUSIONS: High CRP with low HDL-C levels was associated with death and major disability within one year after ischemic stroke. The findings suggest that the ischemic patients with both high CRP and low HDL-C should be treated with reducing CRP and promoting HDL-C levels. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  C-reactive protein; High-density Lipoprotein Cholesterol (HDL-C); atherosclerosis; inflammation; ischemic stroke; stroke.

Mesh:

Substances:

Year:  2018        PMID: 29998802     DOI: 10.2174/1567202615666180712100440

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  3 in total

1.  A novel prognosis prediction model, including cytotoxic T lymphocyte-associated antigen-4, ischemia-modified albumin, lipoprotein-associated phospholipase A2, glial fibrillary acidic protein, and homocysteine, for ischemic stroke in the Chinese hypertensive population.

Authors:  Jin Ma; Likui Shen; Lei Bao; Hua Yuan; Yingxin Wang; Hua Liu; Qiang Wang
Journal:  J Clin Lab Anal       Date:  2021-03-18       Impact factor: 2.352

2.  Elevated Thyroid Autoantibodies Aggravate Stroke Severity in Euthyroidism with Acute Ischemic Stroke.

Authors:  Jingyi Li; Shoulong Hu; Fang Liu; Dapeng Wu; Wei Song; Miao Hui
Journal:  Dis Markers       Date:  2022-02-26       Impact factor: 3.434

Review 3.  Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability.

Authors:  Núria Puig; Elena Jiménez-Xarrié; Pol Camps-Renom; Sonia Benitez
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.